Expert Michael Atkins, MD, reviews data from the ongoing IGNYTE study utilizing RP1 in combination with nivolumab in relapsed/refractory melanoma.
Michael B. Atkins, MD, Georgetown Lombardi Comprehensive Cancer Center
Advertisement
Articles by Michael B. Atkins, MD, Georgetown Lombardi Comprehensive Cancer Center
Advertisement
Latest Updated Articles
The Future Treatment Landscape of RCCDecember 14th 2020
Newly Diagnosed RCC: KEYNOTE-426 and CheckMate-214December 14th 2020
The Biology of RCC and Improved Treatment OutcomesDecember 14th 2020
Risk Assessment and Diagnostic Work-upDecember 14th 2020
Impact of the Phase 3 CheckMate 9ER Trial on PracticeDecember 14th 2020
Tumor Biology in Favorable to Poor-Risk RCCDecember 14th 2020
Advertisement
Advertisement
Trending on OncLive
1
Epcoritamab Plus Lenalidomide/Rituximab Win EU Approval for R/R Follicular Lymphoma
2
Adagrasib Plus Cetuximab Misses OS, PFS End Points in Pretreated KRAS G12C–Mutated CRC
3
Phase 1 Data Highlight Potential Utility for In Vivo CAR T-Cell Therapy in R/R Myeloma
4
FDA Issues CRL to Orviglance for Liver Metastasis Imaging in Patients With Severe Kidney Impairment
5